Scioderm Sells to Amicus Therapeutics for up to $947 Million

Washington, DC – October 2, 2015 – Cooley advised Scioderm on its sale to Amicus Therapeutics. According to the terms of the transaction, Amicus will pay $229 million in stock and cash along with up to $618 million upon achievement of regulatory and sales milestones and $100 million for a priority review voucher.

Scioderm is a privately held, clinical-stage biopharmaceutical company focused on developing innovative therapies to address diseases with high unmet need, including rare diseases. Amicus Therapeutics is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases.

The M&A team advising Scioderm included partner and head of Cooley's M&A practice, Barbara Borden, partner Christian Plaza, and associates Marc Samuel, Eric Dixon, Alison McCormick and Kerry Killeen.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.